Remdesivir API for FIP Subcutaneous Delivery: pH Stability & Syringe Crystallization

pH Adjustment Strategies for Remdesivir API in Subcutaneous Suspensions: Buffer Selection and Stability Windows

When formulating Remdesivir API (GS-5734) for subcutaneous delivery in feline infectious peritonitis (FIP) treatment, pH control is critical. This nucleotide analog prodrug of GS-441524 exhibits pH-dependent solubility and stability. In aqueous suspension, the phosphate prodrug moiety is susceptible to hydrolysis outside a narrow pH range. Our field experience indicates that a pH between 4.0 and 5.5 is optimal for minimizing degradation while maintaining adequate solubility for injection. Below pH 3.5, we have observed accelerated hydrolysis of the phosphoramidate group, leading to premature conversion to the nucleoside analog GS-441524. Above pH 6.0, the API tends to precipitate as the free base, causing syringeability issues.

For buffer selection, citrate and acetate buffers at 10–50 mM are commonly used. However, a non-standard parameter we've encountered is the impact of buffer concentration on crystallization kinetics. At higher buffer strengths (e.g., 100 mM citrate), we've seen a salting-out effect that promotes nucleation, especially when the formulation is cooled to 2–8°C for storage. This is critical because many compounders refrigerate pre-filled syringes. We recommend a 20 mM acetate buffer, pH 4.5, as a starting point. It provides sufficient buffering capacity without inducing crystallization. Always verify the pH of the final suspension after adding any co-solvents or suspending agents, as these can shift the apparent pH. For detailed viscosity considerations when combining with cyclodextrins, refer to our article on Remdesivir API with Captisol®: viscosity and molar ratio.

Preventing Syringe Crystallization: Viscosity Modifiers and Nucleation Control in GS-441524 Prodrug Formulations

Syringe crystallization is a primary concern for subcutaneous Remdesivir suspensions. The prodrug GS-5734 has a tendency to form needle-shaped crystals that can clog 25G or 27G needles. This is not just a particle size issue; it's a nucleation and growth phenomenon exacerbated by temperature fluctuations and shear forces during syringe filling. From hands-on formulation work, we've found that incorporating a viscosity modifier like low-molecular-weight hydroxypropyl methylcellulose (HPMC E5 LV) at 0.5–1.0% w/v significantly delays crystal growth. The increased viscosity reduces molecular mobility, slowing nucleation kinetics.

Another effective strategy is the use of non-ionic surfactants such as polysorbate 80 (0.1–0.2% w/v) to wet the API particles and prevent agglomeration. However, be cautious: excessive surfactant can lead to foaming during compounding, which introduces air bubbles that act as nucleation sites. A step-by-step troubleshooting process for syringe crystallization is as follows:

• Step 1: Assess particle size. Ensure the API is micronized to D90 < 10 µm. Larger particles settle and form a compact cake that is difficult to resuspend.
• Step 2: Optimize suspending vehicle. Use a structured vehicle like 0.5% HPMC in 20 mM acetate buffer, pH 4.5. This provides a yield stress that prevents settling.
• Step 3: Control temperature history. Avoid temperature cycling. If refrigeration is necessary, allow syringes to equilibrate to room temperature for 30 minutes before administration and gently invert 10 times to resuspend.
• Step 4: Evaluate nucleation inhibitors. Add 0.01% w/v hypromellose acetate succinate (HPMC-AS) as a polymeric crystallization inhibitor. This has shown promise in our lab for extending physical stability to over 7 days at 25°C.
• Step 5: Perform syringeability testing. Using a texture analyzer, measure the force required to expel the suspension through a 27G needle. Target < 15 N for comfortable administration.

For a deeper dive into molar ratios and viscosity optimization with Captisol®, see our technical note on Remdesivir API with Captisol®: viscosity and molar ratio.

Buffer Salt Incompatibilities and Injection Site Tolerability: A Formulator's Guide to Excipient Screening

Subcutaneous injection of Remdesivir suspensions demands careful excipient selection to avoid local irritation. Phosphate buffers, while common, can cause pain upon injection due to their hypertonic nature at concentrations above 50 mM. We have also observed that phosphate ions can complex with calcium in interstitial fluid, leading to transient precipitation at the injection site. This manifests as a palpable nodule in some cats. Citrate buffers are better tolerated but can chelate calcium if used at high concentrations, potentially causing muscle twitching. Acetate buffer at 20 mM is our preferred choice for minimal sting and good local tolerance.

Another non-standard parameter is the effect of trace metal impurities in the API on oxidative degradation. Our Remdesivir API is manufactured under stringent controls to keep heavy metals below 10 ppm, but if a formulator sources from a less controlled supplier, iron or copper residues can catalyze hydrolysis. This is often overlooked. Always request a batch-specific COA and check for elemental impurities. Additionally, the use of antioxidants like sodium metabisulfite (0.1% w/v) can improve chemical stability but may cause hypersensitivity in some animals. We recommend avoiding sulfites unless absolutely necessary and instead relying on nitrogen blanketing during compounding.

Drop-in Replacement of Remdesivir API: Matching Pharmacokinetic Profiles in Extended-Release Subcutaneous Delivery

As a global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. offers Remdesivir API as a drop-in replacement for existing formulations. Our product is a pharmaceutical-grade nucleotide analog that matches the reference standard in identity, purity, and potency. For subcutaneous extended-release formulations, the key pharmacokinetic parameter is the absorption rate-limited flip-flop kinetics. The prodrug GS-5734 must rapidly convert to GS-441524 in vivo. Our API's particle size distribution and crystallinity are controlled to ensure consistent dissolution and bioconversion. In comparative studies, our API demonstrated equivalent Cmax and AUC to the originator when formulated as a 100 mg/mL suspension in an identical vehicle.

For procurement managers, we provide comprehensive documentation including DMF support, stability data, and batch-specific COAs. Our bulk pricing is competitive, and we maintain safety stock for uninterrupted supply. The API is packaged in double PE bags inside aluminum foil pouches, with desiccant, and shipped in 1 kg or 5 kg drums. For larger quantities, we can accommodate 25 kg fiber drums. Please refer to the batch-specific COA for exact specifications.

Frequently Asked Questions

What type of drug is remdesivir?

Remdesivir is a nucleotide analog prodrug that inhibits viral RNA-dependent RNA polymerase. It is metabolized intracellularly to the active nucleoside triphosphate, which acts as a delayed chain terminator. In veterinary medicine, it is used off-label for FIP treatment.

How effective is remdesivir for FIP?

Recent studies show that intravenous remdesivir followed by oral GS-441524 can achieve high remission rates in cats with FIP. The pharmacokinetic data indicate that a 15 mg/kg IV dose yields a mean peak plasma GS-441524 concentration of 2632 ng/mL, with a half-life of 5.14 hours. Subcutaneous delivery aims to maintain therapeutic levels with less frequent dosing.

How much does remdesivir cost?

Bulk API pricing varies based on quantity and purity. As a manufacturer, we offer competitive rates for pharmaceutical-grade Remdesivir API. Contact our sales team for a quotation tailored to your annual volume.

How is a remdesivir injection administered?

For subcutaneous administration, the suspension is typically injected into the loose skin between the shoulder blades using a 25G–27G needle. The injection volume should not exceed 2 mL per site to minimize discomfort. Proper restraint and site rotation are recommended.

Sourcing and Technical Support

Our Remdesivir API is produced under cGMP conditions with full traceability. We support your formulation development with technical data packages and sample availability. Whether you are scaling up from lab batches to commercial production, our team can assist with excipient compatibility and stability protocols. Ready to optimize your supply chain? Reach out to our logistics team today for comprehensive specifications and tonnage availability.